Acute Respiratory Distress Syndrome
Conditions
Brief summary
This study will be a multi-center, prospective, randomized, partially double-blind, placebo-controlled Phase II clinical trial of inhaled CO (iCO) for the treatment of ARDS. The trial will be conducted at 7 tertiary care medical centers including Weill Cornell Medicine/NewYork-Presbyterian Hospital, Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH), Duke University Hospital, Durham Veterans Administration Medical Center, New York-Presbyterian Brooklyn Methodist Hospital, and Duke Regional Hospital. The purpose of this study is to evaluate the safety, tolerability, and efficacy of inhaled carbon monoxide (iCO) for the treatment of ARDS and to examine the biologic readouts of low dose iCO therapy in patients with ARDS
Detailed description
Acute respiratory distress syndrome (ARDS) is a devastating disease affecting military, veteran, and civilian populations. ARDS is a syndrome of severe acute lung inflammation and hypoxemic respiratory failure with an incidence of 180,000 cases annually in the United States. Despite recent advances in critical care management and lung protective ventilation strategies, ARDS morbidity and mortality remain unacceptably high. The lack of specific effective therapies for ARDS indicates a need for new treatments that target novel pathways. Carbon monoxide (CO) represents a novel therapeutic modality in ARDS based on data obtained in experimental models of ARDS over the past decade. CO has been shown to be protective in experimental models of acute lung injury (ALI) and sepsis. Furthermore, multiple human studies have demonstrated that experimental administration of several different concentrations of CO is well tolerated and that low dose inhaled CO can be safely administered to subjects in a controlled research environment. The investigators have previously conducted a Phase I trial of low dose iCO in ARDS which demonstrated that precise administration of low dose iCO (100 and 200 ppm) is feasible, well-tolerated, and safe in patients with sepsis-induced ARDS. The purpose of this study is to assess the safety and efficacy of low dose inhaled carbon monoxide (iCO) therapy in mechanically ventilated patients with ARDS.
Interventions
DRUGInhaled Carbon Monoxide at 200 ppm
Inhaled Carbon Monoxide at 200 ppm for 90 minutes daily for 3 days.
OTHERInhaled Medical air
Inhaled Medical Air for up to 90 minutes daily for 3 days.
Sponsors
Brigham and Women's Hospital
Massachusetts General Hospital
Weill Medical College of Cornell University
Duke University
Durham VA Medical Center
New York Presbyterian Brooklyn Methodist Hospital
Duke Regional Hospital
U.S. Army Medical Research Acquisition Activity
Washington University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
The study drug will be blinded to the study staff using identical tanks containing either CO or placebo air. The administering respiratory therapist (RT) and a physician study staff member will be unblinded to the treatment assignments.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All intubated patients ≥ 18 years old with ARDS 1. ARDS is defined when all four of the following criteria are met: 1. A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP) 2. Bilateral opacities on frontal chest radiograph (not fully explained by effusions, lobar/lung collapse, or nodules) within 1 week of a known clinical insult or new or worsening respiratory symptoms 3. A need for positive pressure ventilation by an endotracheal or tracheal tube 4. Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present. 2. ARDS onset is defined as the time the last of criteria 1-4 are met. ARDS must persist through the enrollment time window of 168 hours.
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: 1. Age less than 18 years 2. Greater than 168 hours since ARDS onset 3. Pregnant or breastfeeding 4. Prisoner 5. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) 6. No consent/inability to obtain consent or appropriate legal representative not available 7. Physician refusal to allow enrollment in the trial 8. Moribund patient not expected to survive 24 hours 9. No arterial or central line/no intent to place an arterial or central line 10. No intent/unwillingness to follow lung protective ventilation strategy 11. Severe hypoxemia defined as SpO2 \< 95 or PaO2 \< 90 on FiO2 ≥ 0.9 12. Hemoglobin \< 7.0 g/dL 13. Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization 14. Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days 15. Coronary artery bypass graft (CABG) surgery within 30 days 16. Angina pectoris or use of nitrates with activities of daily living 17. Cardiopulmonary disease classified as NYHA class IV 18. Stroke (ischemic or hemorrhagic) within the prior 1 month, cardiac arrest requiring CPR within the prior 72 hours, or inability to assess mental status following cardiac arrest 19. Burns \> 40% total body surface area (TBSA) 20. Severe airway inhalational injury 21. Use of high frequency oscillatory ventilation 22. Use of extracorporeal membrane oxygenation (ECMO) 23. Concomitant use of inhaled pulmonary vasodilator therapy (eg. nitric oxide \[NO\] or prostaglandins) 24. Diffuse alveolar hemorrhage from vasculitis 25. Concurrent participation in other investigational drug study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Safety Outcome: Number of Pre-specified Administration-related Adverse Events. | 7 days | Safety of inhaled CO, defined by the incidence of pre-specified administration-related AEs (as defined below) and spontaneously reported AEs through study day 7. 1. Acute MI within 48 hours of study drug administration 2. Acute cerebrovascular accident (CVA) within 48 hours of study drug administration 3. New onset atrial or ventricular arrhythmia requiring DC cardioversion within 48 hours of study drug administration 4. Increased oxygenation requirements defined as: an increase in FiO2 of ≥ 0.2 AND increase in PEEP ≥ 5 cm H2O within 6 hours of study drug administration 5. Increase in COHb ≥ 10% 6. Increase in lactate by ≥ 2 mmol/L within 6 hours of study drug administration |
| Primary Efficacy Outcome: Change in Mitochondrial DNA (mtDNA) Level From Day 1 to Day 5 | 5 days | Mitochondrial DNA (mtDNA) plasma levels will be measured by quantitative PCR of human NADH dehydrogenase 1. The number presented is the percentage average difference from beginning to end of treatment. Limited number of measurements prevents variance analyses; therefore we present the data from the subjects available in each group and report as "Mean" without standard deviation, where measures of dispersion cannot be calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lung Injury Score (LIS) on Days 1-5, and on Days 1-7 | 7 days | The Lung Injury Score (LIS) is a composite 4-point scoring system including the PaO2/FiO2, PEEP, quasi-static respiratory compliance, and the extent of infiltrates on the chest X-ray. Each of the four components is categorized from 0 to 4, where a higher number is worse. The total Lung Injury Score is obtained by dividing the aggregate sum by the number of components used. Previous randomized clinical trials in ARDS have shown that a decreased LIS correlates with improvement in lung physiology as well as important clinical outcomes including mortality and ventilator-free days (VFDs). The number presented is the average difference from beginning to end of treatment. The limited number of measurements prevent the variance and measures of dispersion calculations; therefore we present the average of data from the available subjects in each group and report as "Mean" without standard deviation, where measures of dispersion cannot be calculated. |
| Percent Change in PaO2/FiO2 Ratio on Days 1-5, and on Days 1-7 | 7 days | PaO2/FiO2 will be measured daily on days 1-5 and days 1-7 in ventilated subjects. The limited number of measurements prevent the variance and measures of dispersion calculations; therefore we present the average of data from the available subjects in each group and report as "Mean" without standard deviation, where measures of dispersion cannot be calculated. |
| Percent Change in Oxygenation Index (OI) on Days 1-5, and Days 1-7 | 7 days | The oxygenation index will be measured on days 1-5 and on days 1-7 in ventilated subjects. Oxygenation index is calculated as (FiO2 X mean airway pressure)/PaO2. We provide change in Oi from baseline. Oi is only measured when subjects are ventilated, therefore not all timepoints are available. The limited number of measurements prevent the variance and measures of dispersion calculations; therefore we present the average of data from the available subjects in each group and report as "Mean" without standard deviation, where measures of dispersion cannot be calculated. |
| Percent Change in Dead Space Fraction (Vd/Vt) on Days 1-3, and Days 1-7 | 7 days | The dead space fraction will be measured days 1-3 and days 1-7 in ventilated subjects. We present change in dead space fraction between initial and final measurements that were available (measurements only taken while the subjects were intubated). The limited number of measurements prevent the variance and measures of dispersion calculations; therefore we present the average of data from the available subjects in each group and report as "Mean" without standard deviation, where measures of dispersion cannot be calculated. |
| Percent Change in Sequential Organ Failure Assessment (SOFA) Score on Days 1-5, and Days 1-7. | 1-5 and 1-7 days | Organ failure will be assessed using the SOFA score. SOFA scores will be assessed daily on days 1-5 and day 7, as the SOFA score has been shown to be a reliable prognostic indicator of outcomes in critically ill patients. To calculate the Sequential Organ Failure Assessment (SOFA) score, each of the six components (Respiratory, Coagulation, Liver, Cardiovascular, Central Nervous System, Renal) is categorized from 0-4, where a higher number is worse. The SOFA score (0-24) will be calculated by summing all six components. We present changes in SOFA score over the time of hospitalization, over the time of ICU admission (up to days 5 and 7 for the enrolled subjects). The limited number of measurements prevent the variance and measures of dispersion calculations; therefore we present the average of data from the available subjects in each group and report as "Mean" without standard deviation, where measures of dispersion cannot be calculated. |
| Absolute Value of Biomarkers of Inflammation and Inflammasome Activation | 4 days | Cytokine plasma levels (eg. IL-1B) will be measured by ELISA daily on days 1-3 and on day 4. We report the absolute Mean Fluorescent Intensity (MFI) of each sample at pretreatment time point of day 4. Limited number of measurements prevents variance and measures of dispersion analyses; therefore we present the data from the subjects available in each group and report as "Number" without standard deviation, since measures of dispersion cannot be calculated. |
| Percent Change in Lipid Mediators | 4 days | Lipid mediators (LM) and specialized pro-resolving mediators (SPMs) will be measured in plasma using liquid chromatography-tandem mass spectrometry (LC-MS-MS) based methods daily on days 1-3 and on day 4. The percentage change from baseline at day 1 to post treatment at day 4 is reported. A representative LM is shown (14-HDHA (14-hydroxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid) is an oxidized metabolite of omega-3 docosahexaenoic acid (DHA)). Limited number of measurements prevents variance and measures of dispersion analyses; therefore we present the data from the subjects available in each group and report as "Number" without standard deviation, since measures of dispersion cannot be calculated. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRebecca Baron, MD
Brigham and Women's Hospital
Participant flow
Recruitment details
First recruited subject date was 9/30/2019 and last recruited subject was 4/5/2021. The study treatment was 3 days and follow up during 60 days during hospitalization and up to 6 months follow up. Screening was conducted in Intensive Care Units and qualifying subjects were consented by study physicians at Brigham and Women's Hospital, Duke University Hospital and New York Presbyterian Brooklyn Methodist Hospital.
Pre-assignment details
After consent. Subjects were randomized to either placebo or inhaled CO. Study procedures started the following day after randomization. The study recruited a total of 4 subjects and was closed due to low enrollment.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants |
| Baseline Critical Illness: Acute Respiratory Distress Syndrome (ARDS) | 4 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 2 Participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 2 / 3 | 0 / 1 |
| other Total, other adverse events | 0 / 3 | 1 / 1 |
| serious Total, serious adverse events | 3 / 3 | 1 / 1 |
Outcome results
None listed